Savara (NASDAQ:SVRA) Announces Quarterly Earnings Results

Savara (NASDAQ:SVRA) announced its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01), FiscalAI reports.

Savara Stock Performance

Shares of NASDAQ SVRA traded down $0.04 during midday trading on Tuesday, reaching $5.08. 720,880 shares of the company traded hands, compared to its average volume of 1,515,326. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -9.58 and a beta of 0.28. The stock has a 50-day moving average price of $5.40 and a 200 day moving average price of $5.46. Savara has a 52 week low of $1.89 and a 52 week high of $7.01. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.85 and a quick ratio of 11.85.

Analysts Set New Price Targets

A number of research firms have recently commented on SVRA. HC Wainwright restated a “buy” rating on shares of Savara in a report on Monday, March 16th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Oppenheimer started coverage on shares of Savara in a research report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, William Blair set a $10.00 price objective on shares of Savara in a research report on Monday, March 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.13.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Savara in the fourth quarter worth approximately $396,000. Invesco Ltd. lifted its position in shares of Savara by 302.1% in the 4th quarter. Invesco Ltd. now owns 688,595 shares of the company’s stock valued at $4,152,000 after acquiring an additional 517,329 shares in the last quarter. KVP Capital Advisors LP purchased a new stake in shares of Savara in the 4th quarter valued at approximately $3,650,000. Voloridge Investment Management LLC purchased a new stake in shares of Savara in the 4th quarter valued at approximately $520,000. Finally, Wellington Management Group LLP lifted its position in shares of Savara by 1.2% in the 4th quarter. Wellington Management Group LLP now owns 2,674,931 shares of the company’s stock valued at $16,130,000 after acquiring an additional 30,931 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.